Information  X 
Enter a valid email address

EPIC/TIDM matching '0QLR'

Date
Time Source
Company
Announcement
13 Nov 2018 9:28 pm GNW   Factsheet Novartis International AG (0QLR) Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
11 Nov 2018 4:45 pm GNW   Factsheet Novartis International AG (0QLR) New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
05 Nov 2018 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
02 Nov 2018 10:00 pm GNW   Factsheet Novartis International AG (0QLR) Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
  9:15 pm GNW   Factsheet Novartis International AG (0QLR) Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
31 Oct 2018 4:30 pm GNW   Factsheet Novartis International AG (0QLR) Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
29 Oct 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
27 Oct 2018 3:08 pm GNW   Factsheet Novartis International AG (0QLR) Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
26 Oct 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
23 Oct 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Alcon to develop SMART Suite digital health platform for cataract surgery
22 Oct 2018 11:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed
  8:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
20 Oct 2018 3:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
19 Oct 2018 3:00 pm GNW   Factsheet Novartis International AG (0QLR) Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
18 Oct 2018 6:02 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
  6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
16 Oct 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
11 Oct 2018 9:35 pm GNW   Factsheet Novartis International AG (0QLR) Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
10 Oct 2018 9:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden
09 Oct 2018 9:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
08 Oct 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
04 Oct 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
03 Oct 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
22 Sep 2018 1:41 pm GNW   Factsheet Novartis International AG (0QLR) Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
  1:36 pm GNW   Factsheet Novartis International AG (0QLR) New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
21 Sep 2018 12:27 pm GNW   Factsheet Novartis International AG (0QLR) Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
  12:25 pm GNW   Factsheet Novartis International AG (0QLR) Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
  12:24 pm GNW   Factsheet Novartis International AG (0QLR) Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease
17 Sep 2018 9:30 pm GNW   Factsheet Novartis International AG (0QLR) World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
13 Sep 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients
12 Sep 2018 10:00 pm GNW   Factsheet Novartis International AG (0QLR) Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis survey shows psoriasis patients want treatment effect beyond clear skin
11 Sep 2018 6:00 am GNW   Factsheet Novartis International AG (0QLR) Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
06 Sep 2018 3:30 am GNW   Factsheet Novartis International AG (0QLR) Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
29 Aug 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma
  6:00 am GNW   Factsheet Novartis International AG (0QLR) Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
27 Aug 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
25 Aug 2018 10:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
23 Aug 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
14 Aug 2018 6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
30 Jul 2018 9:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
27 Jul 2018 1:53 pm GNW   Factsheet Novartis International AG (0QLR) Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
  1:23 pm GNW   Factsheet Novartis International AG (0QLR) Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
23 Jul 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
19 Jul 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
18 Jul 2018 4:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
  6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
29 Jun 2018 1:10 pm GNW   Factsheet Novartis International AG (0QLR) Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
  6:00 am GNW   Factsheet Novartis International AG (0QLR) Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
28 Jun 2018 9:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine
27 Jun 2018 9:30 pm GNW   Factsheet Novartis International AG (0QLR) Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
26 Jun 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
18 Jun 2018 6:15 am GNW   Factsheet Novartis International AG (0QLR) Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
16 Jun 2018 10:30 am GNW   Factsheet Novartis International AG (0QLR) Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15 Jun 2018 7:40 am GNW   Factsheet Novartis International AG (0QLR) Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
  7:35 am GNW   Factsheet Novartis International AG (0QLR) Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
  6:15 am GNW   Factsheet Novartis International AG (0QLR) Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t